<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430479</url>
  </required_header>
  <id_info>
    <org_study_id>kbcrnb002</org_study_id>
    <nct_id>NCT03430479</nct_id>
  </id_info>
  <brief_title>Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer</brief_title>
  <official_title>Phase Ib/II Study to Assess Efficacy, Safety &amp; Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Breast Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto Breast Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of anti PD-1 antibody with
      radiation therapy in patients with HER2-negative metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib : dose-limiting toxicity rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort A</intervention_name>
    <description>Radiation + Nivolumab + hormone therapy</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Cohort A

          1. Documentation of ER-positive and/or PR-positive tumor (&gt;=1% positive stained cells) .

          2. Patients must satisfy the following criteria for prior therapy:

             - Progressed during treatment or within 12 months of completion of adjuvant hormone
             therapy.

             or Progressed while prior hormone therapy for advanced/metastatic breast cancer. Two
             previous line of hormone therapy for advanced/metastatic disease is allowed.

          3. Patients who have hormone therapy that can be expected for advanced /metastatic
             disease.

             Cohort B

          4. Patients who have come to be non-responsive more than two line of chemotherapy

          5. Prior chemotherapy with anthracycline and taxane agent

             Cohort A and B

          6. Female patients who are histologically or cytologically confirmed to have breast
             cancer

          7. Patients who have distant metastatic lesion as follow

             - More than one bone lesion for radiation therapy

          8. Patients with cancer confirmed to be HER2-negative.（

          9. Patients with a measurable lesion based on RECIST 1.1.

         10. Patients aged &gt;= 20 years at informed consent

         11. Patients with ECOG PS of 0 to 1.

         12. Patients without any severe disorder in the major organs.

         13. Patients expected to survive for ≥ 90 days.

         14. Patients of childbearing potential must be using an acceptable method of contraception
             to avoid pregnancy and must not be breastfeeding for 18 weeks after the last dose of
             investigational product

         15. Patients who have provided written informed consent themselves.

        Exclusion Criteria:

        Exclusion Criteria:

          1. Patients who have neuropathy (more than Grade 2)

          2. Patients with any active autoimmune disease or a history of known autoimmune disease.

          3. Patients who has a history of pneumonitis or interstitial lung disease.

          4. Active, untreated central nervous system metastasis.

          5. Patients with pericardial effusion, pleural effusion or ascites requiring treatment

          6. Patients with uncontrolled diabetes mellitus

          7. Patients with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications within 28 days of the enrollment.

          8. Patients who has received radiotherapy within 28 days of study registration, or
             radiotherapy for thorax within 56 days of the enrollment.

          9. Pregnant or breast-feeding women.

         10. Prior therapy with Nivolumab, anti CTLA-4 antibody therapies, any other antibody or
             drug specifically targeting T-cell co-stimulation or checkpoint pathways

         11. Patients considered ineligible for participation in this study by their attending
             physicians
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kazuo Sakamoto</last_name>
    <phone>+8175-761-5751</phone>
    <email>kbcrn-b-002@kyoto-breast-cancer.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masakazu Toi</last_name>
      <phone>+8175-751-3660</phone>
      <email>toi@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiro Takada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

